A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-high Hypertriglyceridemia.

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-high Hypertriglyceridemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Omega-3 phospholipid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Acronyms TRIFECTA
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 14 Aug 2017 According to an Acasti Pharma media release, select data from this and other studies (COLT, PMRI2016-4010 and CAP13-101) will be submitted for publication in a peer-reviewed journal.
    • 14 Aug 2017 Results from this study were included in an oral presentation at the International Academy of Cardiology Annual Scientific Sessions 22nd World Congress on Heart Disease (WCHD), according to an Acasti Pharma media release.
    • 21 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top